MEDIROM Healthcare Technologies
MRM
0 hedge funds and large institutions have $0 invested in MEDIROM Healthcare Technologies in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $25 → $0 (-$25)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$25 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | -$25 | -4 | Closed |
|
MRM Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in MEDIROM Healthcare Technologies (MRM) for Q2 2023, worth a combined $0 — down 100% from $25 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MRM and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $25 sold.
- 0 institutional investors held MEDIROM Healthcare Technologies (MRM) as of Q2 2023, down from 1 in Q1 2023.
- Funds reported $0 of MEDIROM Healthcare Technologies stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new MEDIROM Healthcare Technologies positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest MEDIROM Healthcare Technologies seller in Q2 2023 was UBS Group, an estimated $25 sold.
Based on aggregated 13F filings for Q2 2023.